Phage-Antibiotic Combination Therapy for Antibiotic-Resistant Bacteria; Synergistic Mechanisms and Clinical Applications: A Systematic Review
Article Sidebar
Main Article Content
Abstract
Background: Antimicrobial resistance (AMR) is a major global health challenge requiring innovative therapeutic strategies. Phage–antibiotic combination therapy has emerged as a potential approach for treating multidrug-resistant (MDR) bacterial infections. This systematic review summarizes reported synergistic effects and clinical outcomes of this combined strategy.
Methods: This review was conducted according to PRISMA guidelines. PubMed, Scopus, Web of Science, and the Cochrane Library were searched for studies published between January 2000 and December 2024 assessing combined bacteriophage and antibiotic therapy against MDR bacteria. Eligible studies focused on therapeutic synergy, bacterial resensitization, and clinical outcomes, with results synthesized narratively.
Results: A total of 25 studies were included, comprising 10 in vitro studies, 7 in vivo animal studies, and 8 clinical investigations. Phage–antibiotic combinations demonstrated synergistic effects in more than 70% of cases, resulting in enhanced bacterial eradication, improved biofilm disruption, and reduced resistance development compared with monotherapy. The mean Fractional Inhibitory Concentration Index (FIC-I) for synergistic combinations in in vitro studies was 0.29±0.11. Animal studies reported protection or survival rates ranging from 64% to 100%. Clinical reports, including case studies and one phase 2 trial, documented successful treatment of refractory MDR infections without major safety concerns, although adverse events were inconsistently reported.
Conclusion: Phage–antibiotic combination therapy appears to be a promising approach for managing MDR bacterial infections. Despite encouraging evidence of enhanced efficacy, challenges such as phage resistance, host immune responses, and variability in interactions remain. Larger, well-designed clinical trials and individualized testing are necessary to confirm clinical efficacy and optimize therapeutic application.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. Phage treatment of human infections. Bacterio-phage. 2011;1(2):66-85. https://doi.org/10.4161/bact.1.2.15845
Abedon ST. Phage-antibiotic combination treat-ments: antagonistic impacts of antibiotics on the pharmacodynamics of phage therapy?. Antibiotics. 2019 Oct 11;8(4):182. https://doi.org/10.3390/antibiotics8040182
Anastassopoulou C, Ferous S, Petsimeri A, Gioula G, Tsakris A. Phage-based therapy in combination with antibiotics: a promising alternative against multidrug-resistant Gram-negative pathogens. Pathogens. 2024 Oct 14;13(10):896./ https://doi.org/10.3390/pathogens13100896
Bao J, Wu N, Zeng Y, Chen L, Li L, Yang L, Zhang Y, et al. Non-active antibiotic and bacterio-phage synergism to successfully treat recurrent uri-nary tract infection caused by extensively drug-resistant Klebsiella pneumoniae. Emerg Microbes & Infect. 2020 Jan 1;9(1):771-4. https://doi.org/10.1080/22221751.2020.1747950
Braunstein R, Hubanic G, Yerushalmy O, Oren-Alkalay S, Rimon A, Coppenhagen-Glazer S, et al. Successful phage-antibiotic therapy of P. aerugino-sa implant-associated infection in a Siamese cat. Vet Q. 2024 Dec 31;44(1):1-9. https://doi.org/10.1080/01652176.2024.2350661
Chaturongakul S, Ounjai P. Phage-host interplay: examples from tailed phages and Gram-negative bacterial pathogens. Front Microbiol. 2014 Aug 20;5:442. https://doi.org/10.3389/fmicb.2014.00442
Chen X, Liu M, Zhang P. Phage-derived depoly-merase as an antibiotic adjuvant against multidrug-resistant Acinetobacter baumannii. Front Microbiol 2022; 13: 845500 [(Internet]). https://doi.org/10.3389/fmicb.2022.845500
Coyne AJ, Stamper K, Kebriaei R, Holger DJ, El Ghali A, Morrisette T, et al. Phage cocktails with daptomycin and ampicillin eradicates biofilm-embedded multidrug-resistant Enterococcus faeci-um with preserved phage susceptibility. Antibiotics (Basel). 2022 Aug 30;11(9):1175. https://doi.org/10.3390/antibiotics11091175
Easwaran M, De Zoysa M, Shin HJ. Application of phage therapy: Synergistic effect of phage EcSw (ΦEcSw) and antibiotic combination towards anti-biotic‐resistant Escherichia coli. Transbound Emerg Dis. 2020 Nov;67(6):2809-17. https://doi.org/10.1111/tbed.13646
Ferry T, Kolenda C, Laurent F, Leboucher G, Me-rabischvilli M, Djebara S, et al. Personalized bacteri-ophage therapy to treat pandrug-resistant spinal Pseudomonas aeruginosa infection. Nat Commun. 2022 Jul 22;13(1):4239./ https://doi.org/10.1038/s41467-022-31837-9
Gaborieau B, Delattre R, Adiba S, Clermont O, Denamur E, Ricard JD, Debarbieux L. Variable fit-ness effects of bacteriophage resistance mutations in Escherichia coli: implications for phage therapy. J Virol. 2024 Oct 22;98(10):e01113-24. https://doi.org/10.1128/jvi.01113-24
Gu Liu C, Green SI, Min L, Clark JR, Salazar KC, Terwilliger AL, et al. Phage-antibiotic synergy is driven by a unique combination of antibacterial mechanism of action and stoichiometry. MBio. 2020 Aug 25;11(4):10-128. https://doi.org/10.1128/mBio.01462-20
Holger DJ, Lev KL, Kebriaei R, Morrisette T, Shah R, Alexander J, Lehman SM, Rybak MJ. Bacterio-phage‐antibiotic combination therapy for multi-drug‐resistant Pseudomonas aeruginosa: In vitro synergy testing. J Appl Microbiol. 2022 Sep 1;133(3):1636-49. https://doi.org/10.1111/jam.15647
Huff WE, Huff GR, Rath NC, Balog JM, Do-noghue AM. Therapeutic efficacy of bacteriophage and Baytril (enrofloxacin) individually and in com-bination to treat colibacillosis in broilers. Poult Sci. 2004 Dec 1;83(12):1944-7. https://doi.org/10.1093/ps/83.12.1944
Jansen M, Wahida A, Latz S, Krüttgen A, Häfner H, Buhl EM, Ritter K, Horz HP. Enhanced antibac-terial effect of the novel T4-like bacteriophage KARL-1 in combination with antibiotics against multi-drug resistant Acinetobacter baumannii. Sci Rep. 2018 Sep 20;8(1):14140. https://doi.org/10.1038/s41598-018-32344-y
Kamal F, Dennis JJ. Burkholderia cepacia complex phage-antibiotic synergy (PAS): antibiotics stimu-late lytic phage activity. Appl Environ Microbiol. 2015 Feb 1;81(3):1132-8. https://doi.org/10.1128/AEM.02850-14
Kim P, Sanchez AM, Penke TJ, Tuson HH, Kime JC, McKee RW, et al. Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncom-plicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomized, open-label, first part of a two-part phase 2 trial. Lancet Infect Dis. 2024 Dec 1;24(12):1319-32. https://doi.org/10.1016/S1473-3099(24)00424-9
Kunz Coyne AJ, Stamper K, El Ghali A, Kebriaei R, Biswas B, Wilson M, et al. Phage-antibiotic cocktail rescues daptomycin and phage susceptibil-ity against daptomycin-nonsusceptible Enterococ-cus faecium in a simulated endocardial vegetation ex vivo model. Microbiol Spectr. 2023 Aug 17;11(4):e00340-23. https://doi.org/10.1128/spectrum.00340-23
Law N, Logan C, Yung G, Furr CL, Lehman SM, Morales S, et al. Successful adjunctive use of bacte-riophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient. Infection. 2019 Aug 1;47(4):665-8. https://doi.org/10.1007/s15010-019-01319-0
Li X, He Y, Wang Z, Wei J, Hu T, Si J, et al. A combination therapy of Phages and Antibiotics: Two is better than one. Int J Biol Sci. 2021 Aug 18;17(13):3573. https://doi.org/10.7150/ijbs.60551
Lin Y, Chang RY, Britton WJ, Morales S, Kutter E, Chan HK. Synergy of nebulized phage PEV20 and ciprofloxacin combination against Pseudomo-nas aeruginosa. Int J Pharmaceutics. 2018 Nov 15;551(1-2):158-65. https://doi.org/10.1016/j.ijpharm.2018.09.024
Loganathan A, Bozdogan B, Manohar P, Na-chimuthu R. Phage-antibiotic combinations in var-ious treatment modalities to manage MRSA infec-tions. Front Pharmacol. 2024 Apr 9;15:1356179 https://doi.org/10.3389/fphar.2024.1356179
Mekontso Dessap A, Ricard JD, Contou D, Desnos C, Decavèle M, Sonneville R, et al. Melatonin for prevention of delirium in patients receiving me-chanical ventilation in the intensive care unit: a multiarm multistage adaptive randomized con-trolled clinical trial (DEMEL). Intensive Care Med. 2025 Jul 3:1-4.
Moryl M, Szychowska P, Dziąg J, Różalski A, Torzewska A. The combination of phage therapy and β-Lactam antibiotics for the effective treatment of Enterococcus faecalis infections. Int J Mol Sci. 2024 Dec 24;26(1):11. https://doi.org/10.3390/ijms26010011
Mukhopadhyay S, Zhang P, To KK, Liu Y, Bai C, Leung SS. Sequential treatment effects on phage-antibiotic synergistic application against multi-drug-resistant Acinetobacter baumannii. Int J Antimicrob Agent. 2023 Nov 1;62(5):106951. https://doi.org/10.1016/j.ijantimicag.2023.106951
North OI, Brown ED. Phage-antibiotic combina-tions: a promising approach to constrain resistance evolution in bacteria. Ann N Y Acad Sc. 2021 Jul;1496(1):23-34. https://doi.org/10.1111/nyas.14533
Oechslin F, Piccardi P, Mancini S, Gabard J, Moreillon P, Entenza JM, Resch G, Que YA. Syn-ergistic interaction between phage therapy and an-tibiotics clears Pseudomonas aeruginosa infection in endocarditis and reduces virulence. J Infect Dis. 2017 Mar 1;215(5):703-12. https://doi.org/10.1093/infdis/jiw632
Osman AH, Kotey FC, Odoom A, Darkwah S, Yeboah RK, Dayie NT, et al. The potential of bac-teriophage-antibiotic combination therapy in treat-ing infections with multidrug-resistant bacteria. Antibiotics. 2023 Aug 17;12(8):1329. https://doi.org/10.3390/antibiotics12081329
Parab L, Dherbey JR, Rivera N, Schwarz M, Gallie J, Bertels F. Chloramphenicol and gentamicin re-duce resistance evolution to phage ΦX174 by sup-pressing a subset of E. coli C LPS mutants. bio-Rxiv. 2023 Aug 28:2023-08 https://doi.org/10.1101/2023.08.28.552763
Pirnay JP, Djebara S, Steurs G, Griselain J, Cochez C, De Soir S, et al. Personalized bacteriophage ther-apy outcomes for 100 consecutive cases: a multi-center, multinational, retrospective observational study. Nature Microbiol. 2024 Jun;9(6):1434-53.
Schooley RT, Biswas B, Gill JJ, Hernandez-Morales A, Lancaster J, Lessor L, et al. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated re-sistant Acinetobacter baumannii infection. Antimi-crob Agents Chemother. 2017 Oct;61(10):10-128. https://doi.org/10.1128/AAC.00954-17
Stellfox ME, Fernandes C, Shields RK, Haidar G, Hughes Kramer K, Dembinski E, et al. Bacterio-phage and antibiotic combination therapy for recur-rent Enterococcus faecium bacteremia. MBio. 2024 Mar 13;15(3):e03396-23 https://doi.org/10.1128/mbio.03396-23
Suh GA, Lodise TP, Tamma PD, Knisely JM, Al-exander J, Aslam S, et al. Considerations for the use of phage therapy in clinical practice. Antimicrob Agents Chemother. 2022;66(3):e02071-21. https://doi.org/10.1128/aac.02071-21
Supina BS, Dennis JJ. The Current Landscape of Phage-Antibiotic Synergistic (PAS) Interactions. Antibiotics. 2025 May 27;14(6):545. https://doi.org/10.3390/antibiotics14060545
Terwilliger A, Clark J, Karris M, Hernandez-Santos H, Green S, Aslam S, et al. Phage therapy related microbial succession associated with successful clinical outcome for a recurrent urinary tract infec-tion. Viruses. 2021 Oct 12;13(10):2049. https://doi.org/10.3390/v13102049
Torres-Barceló C, Hochberg ME. Evolutionary ra-tionale for phages as complements of antibiotics. Trends Microbiol. 2016;24(4):249-56. https://doi.org/10.1016/j.tim.2015.12.011
Uyttebroek S, Chen B, Onsea J, Ruythooren F, Debaveye Y, Devolder D, et al. Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review. Lancet Infect Dis. 2022 Aug 1;22(8):e208-20. https://doi.org/10.1016/S1473-3099(21)00612-5
Vagima Y, Gur D, Aftalion M, Moses S, Levy Y, Makovitzki A, et al. Phage therapy potentiates sec-ond-line antibiotic treatment against pneumonic plague. Viruses. 2022 Mar 26;14(4):688. https://doi.org/10.3390/v14040688
Wang Z, Cai R, Wang G, Guo Z, Liu X, Guan Y, et al. Combination therapy of phage vB_KpnM_P-KP2 and gentamicin combats acute pneumonia caused by K47 serotype Klebsiella pneumoniae. Front Microbiol. 2021 Apr 22;12:674068. https://doi.org/10.3389/fmicb.2021.674068
Weissfuss C, Li J, Behrendt U, Hoffmann K, Bür-kle M, Tan C, et al. Adjunctive phage therapy im-proves antibiotic treatment of ventilator-associated-pneumonia with Pseudomonas aeruginosa. Nat Commun. 2025 May 15;16(1):4500. https://doi.org/10.1038/s41467-025-59806-y
Wintachai P, Phaonakrop N, Roytrakul S, Naknaen A, Pomwised R, Voravuthikunchai SP, et al. En-hanced antibacterial effect of a novel Friunavirus phage vWU2001 in combination with colistin against carbapenem-resistant Acinetobacter bau-mannii. Sci Rep. 2022 Feb 16;12(1):2633. https://doi.org/10.1038/s41598-022-06582-0
Wu Y, Wang R, Xu M, Liu Y, Zhu X, Qiu J, et al. A novel polysaccharide depolymerase encoded by the phage SH-KP152226 confers specific activity against multidrug-resistant Klebsiella pneumoniae via biofilm degradation. Front Microbiol. 2019 Dec 3;10:2768. https://doi.org/10.3389/fmicb.2019.02768